The excessive greasiness of the hair and skin generally disappears earlier. Treatment with Cyproterone acetate + Ethinylestradiol (Diane-35) leads - usually after 3 to 4 months of therapy - to the healing of existing acne efflorescences. The most recent data suggest that the frequency of VTE diagnosis is approximately 4 per 10,000 woman years in non-pregnant non-COC users, and ranges between 20 to 30 per 10,000 pregnant women or postpartum. Post Authorization Safety Studies (PASS) have shown that the frequency of VTE diagnosis ranges between 7-10 per 10,000 woman years in low estrogen dose (< 50 μg ethinylestradiol) COC users. It thereby reduces free, biologically available androgen in the circulation.
This antigonadotropic effect is amplified by ethinylestradiol which up-regulates as well the synthesis of Sexual-Hormone-Binding-Globulin (SHBG) in plasma.
Both substances contained in Cyproterone acetate + Ethinylestradiol (Diane-35) influence beneficially the hyperandrogenic state: Cyproterone acetate is a competitive antagonist on the androgen receptor, has inhibitory effects on the androgen-synthesis in target cells and produces a decrease of the androgen blood concentration through an antigonadotropic effect.
Acne, seborrhea, hirsutism and androgenetic alopecia are clinical conditions resulting from aberrations of this target organ which may be caused by increased sensitivity or higher plasma levels of androgen. Pharmacology: Pharmacodynamics: The pilosebaceous unit - consisting of the sebaceous gland and the hair follicle - is an androgen-sensitive skin component.
0 kommentar(er)
